Details
Stereochemistry | RACEMIC |
Molecular Formula | C23H32N2O6 |
Molecular Weight | 432.51 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(OCC(O)CN2CCN(CC2)C3=C(OC)C=CC=C3)=CC(OC)=C1OC
InChI
InChIKey=KSQCNASWXSCJTD-UHFFFAOYSA-N
InChI=1S/C23H32N2O6/c1-27-20-8-6-5-7-19(20)25-11-9-24(10-12-25)15-17(26)16-31-18-13-21(28-2)23(30-4)22(14-18)29-3/h5-8,13-14,17,26H,9-12,15-16H2,1-4H3
Molecular Formula | C23H32N2O6 |
Molecular Weight | 432.51 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2236459
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2236459
Enciprazine also known as WY-48624 or, D-3112 is a GABA A receptor agonist which was in the phase III of clinical trial for the treatment of anxiety disorders. Enciprazine was well tolerated, with low levels of sedative and asthenic side effects reported. However, research was discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GABA A receptor Sources: http://adisinsight.springer.com/drugs/800000720 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 27.5404 uM] | ||||
inconclusive [IC50 34.6713 uM] | ||||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2236459
5-week, double-blind trial comparing three dose strengths of enciprazine (5 mg t.i.d., 10 mg t.i.d., and 20 mg t.i.d.) to placebo. A dose escalation was permitted after 2 weeks of active drug treatment, which 61 percent of patients overall took advantage of.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:33:18 GMT 2023
by
admin
on
Fri Dec 15 15:33:18 GMT 2023
|
Record UNII |
L6X660925G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000080205
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
C73209
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
4820
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
DTXSID3057806
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL101284
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
m717
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
68576-86-3
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
SUB06520MIG
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
L6X660925G
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
Enciprazine
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
C057238
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY | |||
|
50222
Created by
admin on Fri Dec 15 15:33:18 GMT 2023 , Edited by admin on Fri Dec 15 15:33:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |